Author

Raffaele Di Francia

National Cancer Institute - Cited by 1,978 - Pharmacology

Biography

Raffaele Di Francia is employed in the laboratory of molecular hematology the National Institute of Tumours of Naples Italy He gained a Degree in Pharmacy Biology at the University of Naples Federico II. He earned his PhD in Clinical Pathology Clinical Chemistry area at University of Udine, Italy having Tutor Professor Rosaria De Filippi. He has published several papers on molecular diagnostics fields and he served as a reviewer of peer reviewed journals in the area of molecular biology. 
Title
Cited by
Year
Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey
M Berretta, C Della Pepa, P Tralongo, A Fulvi, F Martellotta, A Lleshi, ...Oncotarget 8 (15), 24401, 2017201
145
2017
Angiogenesis inhibitors for the treatment of hepatocellular carcinoma
M Berretta, L Rinaldi, F Di Benedetto, A Lleshi, V De Re, G Facchini, ...Frontiers in Pharmacology 7, 428, 2016201
78
2016
Resveratrol in cancer patients: from bench to bedside
M Berretta, A Bignucolo, R Di Francia, F Comello, G Facchini, ...International journal of molecular sciences 21 (8), 2945, 2020202
68
2020
Multiple effects of ascorbic acid against chronic diseases: Updated evidence from preclinical and clinical studies
M Berretta, V Quagliariello, N Maurea, R Di Francia, S Sharifi, G Facchini, ...Antioxidants 9 (12), 1182, 2020202
54
2020
Drug–drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection
M Berretta, M Caraglia, F Martellotta, S Zappavigna, A Lombardi, C Fierro, ...Frontiers in pharmacology 7, 71, 2016201
54
2016
Physician attitudes and perceptions of complementary and alternative medicine (CAM): a Multicentre Italian study
M Berretta, L Rinaldi, R Taibi, P Tralongo, A Fulvi, V Montesarchio, ...Frontiers in oncology 10, 594, 2020202
48
2020
Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers
R Di Francia, S Crisci, A De Monaco, C Cafiero, A Re, G Iaccarino, ...Cancers 13 (5), 966, 2021202
43
2021
Overview of targeted drugs for mature B-cell non-hodgkin lymphomas
S Crisci, R Di Francia, S Mele, P Vitale, G Ronga, R De Filippi, M Berretta, ...Frontiers in oncology 9, 443, 2019201
33
2019
Serum and tissue markers in colorectal cancer: State of art
M Berretta, L Alessandrini, C De Divitiis, G Nasti, A Lleshi, R Di Francia, ...Critical Reviews in Oncology/Hematology 111, 103-116, 2017201
29
2017
Overview of current targeted anti-cancer drugs for therapy in onco-hematology
S Crisci, F Amitrano, M Saggese, T Muto, S Sarno, S Mele, P Vitale, ...Medicina 55 (8), 414, 2019201
28
2019
Sonoporation by microbubbles as gene therapy approach against liver cancer
L Rinaldi, V Folliero, L Palomba, C Zannella, R Isticato, R Di Francia, ...Oncotarget 9 (63), 32182, 2018201
26
2018
Novel medicinal mushroom blend as a promising supplement in integrative oncology: A multi-tiered study using 4t1 triple-negative mouse breast cancer model
E Roda, F De Luca, C Di Iorio, D Ratto, S Siciliani, B Ferrari, F Cobelli, ...International Journal of Molecular Sciences 21 (10), 3479, 2020202
22
2020
Coffee consumption is not associated with ovarian cancer risk: a dose-response meta-analysis of prospective cohort studies
M Berretta, A Micek, A Lafranconi, S Rossetti, R Di Francia, P De Paoli, ...Oncotarget 9 (29), 20807, 2018201
21
2018
Antioxidant diet and genotyping as tools for the prevention of liver disease
R Di Francia, L Rinaldi, M Cillo, E Varriale, G Facchini, C D’Aniello, ...Eur. Rev. Med. Pharmacol. Sci 20, 5155-5163, 2016201
21
2016
Oncological impact of M-Tor inhibitor immunosuppressive therapy after liver transplantation for hepatocellular carcinoma: review of the literature
G Tarantino, P Magistri, R Ballarin, R Di Francia, M Berretta, ...Frontiers in Pharmacology 7, 387, 161
20
2016
New and old assumptions on lung cancer in people living with HIV
F d’Aleo, BAV Cama, IA Paolucci, E Venanzi Rullo, F Condorelli, ...WORLD CANCER RESEARCH JOURNAL 5 (1), 1036-1043, 202
18
2018
Pharmacological profile and pharmacogenomics of anti-cancer drugs used for targeted therapy
R Di Francia, A De Monaco, M Saggese, G Iaccarino, S Crisci, F Frigeri, ...Current Cancer Drug Targets 18 (5), 499-511, 2018201
14
2018
Correlation between individual inflammation genetic profile and platelet rich plasma efficacy in hair follicle regeneration: a pilot study reveals prognostic value of IL-1a …
F Rossano, S Di Martino, L Iodice, M Di Paolo, S Misso, R Tomeo, ...Eur Rev Med Pharmacol Sci 21 (22), 5247-5257, 2017201
12
2017
Pharmacogenomics and pharmacogenetics: in silico prediction of drug effects in treatments for novel coronavirus SARS-CoV2 disease
C Cafiero, A Re, A Micera, R Palmirotta, D Monaco, F Romano, C Fabrizio, ...Pharmacogenomics and Personalized Medicine, 463-484, 2020202
12
2020
Multimodal approach of advanced gastric cancer: based therapeutic algorithm
S Berretta, M Berretta, F Fiorica, R Di Francia, P Magistri, G Bertola, ...European review for medical and pharmacological sciences 20 (19), 4018-4031, 2016201
12
2016

Referred From: https://scholar.google.com/citations?user=ZNXLNSYAAAAJ&hl=en

Cited by
Citations 1978
h-index 27
i10-index 57
Recommended Journals
Open Access Journals